Breakthrough Science Requires Collaboration with Other Leaders in Gene Modification and Gene Therapy

Seraph Research Institute, Los Angeles, CA

Seraph Research Institute (“SRI”) is a non-profit research institution, registered with the U.S. Department of Health and Human Services (HHS) that works to advance medical science in the areas of unmet need. SRI studies gene and cell therapy particularly in the context of cancer (hematological and solid tumors), developing novel stem cell transplant methods for rare diseases, and innate molecular and cellular immunology in cancer and chronic infections like HIV/AIDS and HBV. Seraph Research Institute’s main objective is to develop better stem cell transplant, and cell and gene therapy treatments for patients with cancer, rare genetic disorders, and infectious diseases.

Enochian BioSciences, Inc., announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference 2021.
Link to Poster Presentation

Enochian BioSciences announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Dr. Gumrukçu and SRI are currently pursuing a regulatory pathway with the FDA to study the approach in more patients. Enochian BioSciences holds the exclusive license for the proprietary technology.

Immunotherapeutic Potential of Inhibitory KIR/HLA Mismatched Allogeneic NK and gamma-delta T Cells as an HIV Cure Strategy as presented by Serhat Gumrukcu, MD PhD –Seraph Research Institute at ASGCT 2021

Link to Powerpoint Presentation

Link to Video Presentation

We are excited to announce that Enochian BioSciences has entered into a license agreement, with G Tech Bio, LLC and Seraph Research Institute to acquire the exclusive license to research, develop and commercialize certain formulations aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including SARS-Coronovirus that causes COVID-19 from as recently presented at the 2021 Conference on Retroviruses and Opportunistic Infections (“CROI”) and at the 2020 Conference of American Society of Gene and Cell Therapy (“ASGCT”).

A Novel COVID-19 Cure Strategy: Hijacking SARS-COV-2 RNA-Dependent RNA Polymerase as presented by Serhat Gumrukcu, MD PhD – Seraph Research Institute at CROI 2021.

Link to Powerpoint Presentation

Link to Video Presentation

A Novel Approach to Potentially Treat Influenza: Selective Induction of Apoptosis in Infected Cells by Hijacking the Virus Machinery as presented by Serhat Gumrukcu, MD PhD – Seraph Research Institute at ASGCT 2020.

Link to Powerpoint Presentation

Link to Video Presentation

Scripps Research, La Jolla, CA

Enochian and Scripps Research, one of the most notable medical research institutions in the world, entered a fee-for-service agreement to conduct a series of syngeneic and humanized mice studies. The research is being conducted in the laboratory of Phillippe Gallay, PhD, Professor of Immunology in the Scripps Research Department of Immunology and Microbiology. We believe this agreement will help advance the pre-clinical work necessary to obtain an Investigational New Drug application (IND) with the FDA and provide further valuable insights into the HIV program.

Dong Sung An, MD, PhD, Professor at UCLA

Enochian also entered into an R&D agreement with Dong Sung An, MD, PhD, professor at UCLA. The team focuses on employing genetic modification techniques to make the human population resistant to HIV. Professor An will support the company’s pre-clinical development program, including but not limited to viral vector design. His laboratory will also conduct studies in cells transduced with genes to protect them from infection for HIV. UCLA is one of the leading academic centers in the field of HIV/AIDS research. Dr. An’s prior work for vector designs for an efficient stem cell gene modification to develop anti-HIV will provide valuable insights to Enochian HIV program.

Hitachi Chemical Advanced Therapeutics Solutions (HCATS)

Enochian and HCATS (ex-PCT Cell Therapy Services), one of the world’s largest cell therapy contract development and manufacturing organization (CDMO), signed an agreement to perform a manufacturing assessment of Enochian Biosciences’ ENO-1001 in support of Enochian’s efforts to develop the CMC section of ENO-1001. This agreement allows Enochian Biosciences to leverage HCATS’ extensive experience in cell therapy development and manufacturing technology and wide-ranging manufacturing locations and we believe will allow us to provide clinical supply for our clinical trials in the future.

Katherine Bar, MD, Professor and Director of the Center for AIDS Research, University of Pennsylvania

Dr. Bar is a leading HIV clinician and researcher. Her laboratory developed a Simian-Human Immunodeficiency Virus (SHIV) used in important non-human primate studies. Dr. Bar is collaborating on the study of Enochian’s preventive and therapeutic HIV vaccine studies in non-human primates, including providing the SHIV to be used.

Timothy Block, PhD, the Hepatitis B Foundation and the Baruch S. Blumberg Institute

Dr. Block is the Co-Founder and President of both the Hepatitis B Foundation and the Blumberg Institute. He is one of the top thought leaders and researchers in the field of hepatitis B virus (HBV). Enochian is collaborating with Dr. Block and laboratories at the Blumberg Institute to evaluate the mechanism of action of our potential HBV treatment or cure.